CRISPR Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2013)

Organization Overview

First Clinical Trial
2018
NCT03655678
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

CRISPR Therapeutics | CRISPR Therapeutics AG

Active Ingredients

Drugs in Phase 3 Trials (1)

Exagamglogene autotemcel (Casgevy) (5 trials)

Drugs in Phase 2 Trials (4)

ctx110 (1 trial)

ctx112 (1 trial)

ctx131 (1 trial)

vctx211 (1 trial)

Drugs in Phase 1 Trials (3)

ciltacabtagene autoleucel (Carvykti) (1 trial)

ctx130 (2 trials)

vctx210a (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

beta-Thalassemia (Phase 2)

Carcinoma (Phase 1)

Carcinoma, Renal Cell (Phase 1)

Genetic Diseases, Inborn (Phase 2)

Hematologic Diseases (Phase 2)

Hemoglobinopathies (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 1)

Thalassemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 8